X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Sojournix has resumed its Phase 2 trial of SJX-653, a novel, potent, and selective neurokinin 3 (NK3) antagonist in development as a non-hormonal once-daily treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, commonly called hot flashes.
Lead Product(s): SJX‑653
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SJX‑653
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
Poster presentation of data showing SJX-653 exhibits a potent NK3 antagonist profile across in vitro studies, in vivo models, and initial clinical studies in men and postmenopausal women, will be presented at the 2020 North American Menopause Society Virtual Annual Meeting.
Lead Product(s): SJX-653
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SJX-653
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
SJX-653 demonstrated statistically significant and dose-dependent effects on pharmacodynamic markers of NK3 antagonism. SJX-653 exhibited a plasma half-life supporting once-daily (QD) dosing and was well tolerated.
Lead Product(s): SJX-653
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: SJX-653
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
The Phase 2 clinical trial is a 12-week, multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of SJX-653 in reducing vasomotor symptoms.
Lead Product(s): SJX-653
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
